AGIO · Agios Pharmaceuticals, Inc.
$36.36
-2.65% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-8.1
Dividend yield
—
Beta
0.54
Avg volume
1M
Employees
1K
2D change
1.68%
5D change
1.90%
10D change
-6.66%
30D change
-2.45%
60D change
25.75%
MTD change
-0.30%
YTD change
35.82%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AGIO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-21
Latest call per bank · past 12 months
RBC Capital
Sector Perform$32.00
-12.0% vs priceBank of America
Buy$46.00
+26.5% vs priceJP Morgan
Neutral$31.00
-14.7% vs priceGoldman Sachs
Neutral$32.00
-12.0% vs priceCitigroup
Buy$46.00
+26.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | HC Wainwright & Co. | Maintains | Buy | $54.00 → $52.00 |
| 2026-07-07 | RBC Capital | Maintains | Sector Perform | $28.00 → $32.00 |
| 2026-07-07 | Truist Securities | Maintains | Buy | $36.00 → $41.00 |
| 2026-07-07 | Bank of America | Maintains | Buy | $40.00 → $46.00 |
| 2026-06-15 | HC Wainwright & Co. | Reiterates | Buy | $0.00 → $54.00 |
| 2026-06-11 | JP Morgan | Maintains | Neutral | $36.00 → $31.00 |
| 2026-05-29 | Bank of America | Maintains | Buy | $41.00 → $40.00 |
| 2026-04-30 | Truist Securities | Maintains | Buy | $39.00 → $36.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.6% above the 50-day MA ($33.77).
- Price vs 200-day MA: Trading 13.2% above the 200-day MA ($31.79).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.85) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($22.34) and high ($45.49).
AGIO Price Chart
Loading chart for AGIO…
Fundamentals
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.